BRISTOL MYERS SQUIBB

S.K., D.A.M., J.P., H.S., X.Z., P.H., T.X., and H.S. have financial ties to various pharmaceutical companies, including stock ownership and advisory roles. F.C., J.D., E.V.C., H.S.W., T.Y., R.Y., and J.T. also report consulting or advisory roles and research funding from multiple institutions and companies.

Senator Bernie Sanders will lead a Senate HELP Committee hearing on Ozempic and Wegovy prices, focusing on price controls despite R&D costs and potential harm to medical innovation. The hearing aims to address the high cost of these diabetes medicines, but critics argue it overlooks the significant R&D investments required and the broader implications for future drug development.

VerImmune Inc. secures $4.5 million in Pre-Series A funding led by Beiley Biofund. The company plans to advance its ViP-based therapeutics, including the lead product VERI-101, a cancer immunotherapy. New board members Dr. Che Hsu and Dr. Marta New bring extensive experience in novel modalities.

Prime Minister Narendra Modi held a roundtable with tech CEOs in New York to boost India-US cooperation in AI, Quantum Computing, Biotechnology, Life Sciences, IT, and Semiconductors. Modi emphasized India's potential as a global tech hub, inviting companies to co-develop, co-design, and co-produce in India. CEOs expressed interest in expanding investments and collaborations, highlighting India's innovation-friendly policies and rapid digital expansion.

Over 1 billion people worldwide live with obesity, a global health crisis affecting all income levels. Treatments include lifestyle modification, pharmacotherapies, and bariatric surgery, but implementation gaps exist. Multidisciplinary approaches and patient-centricity are crucial for effective management and clinical trials, addressing social determinants of health and diverse patient needs.

The FDA is set to share results on Bristol Myers Squibb’s KarXT for schizophrenia, which targets muscarinic receptors. KarXT, a combination of xanomeline and trospium, shows potential as a breakthrough treatment with a unique mechanism and fewer adverse effects. The approval could lead to further innovations in schizophrenia treatment, aiming for safer, more effective, and easier-to-use medications.

Bristol Myers Squibb awaits FDA decision on KarXT, a novel schizophrenia treatment potentially representing the first new approach in decades. KarXT, acquired via $14 billion deal with Karuna Therapeutics, targets M1 and M4 muscarinic receptors, offering efficacy without antipsychotic side effects. Other companies, including Neurocrine Biosciences, AbbVie, Reviva Pharmaceuticals, Boehringer Ingelheim, and Alto Neuroscience, are also developing schizophrenia treatments, focusing on various mechanisms to address positive, negative, and cognitive symptoms.

VerImmune Inc. secures $4.5 million in Pre-Series A financing, led by Beiley Biofund, to advance its Virus-inspired Particle (ViP™) platform technology. The funding will support the development of VERI-101, a first-in-class cancer immunotherapy, and expand strategic partnerships. The company also adds Dr. Che Hsu and Dr. Marta New to its Board of Directors.

PM Modi held a 'fruitful' roundtable with US tech CEOs in NY, discussing AI, quantum, biotech, computing, and semiconductors. He emphasized India's growth prospects, IP protection, and fostering tech innovation, aiming to make India a global hub for semiconductor manufacturing and a biotech powerhouse.

Prime Minister Modi interacted with tech CEOs in New York, focusing on AI, Quantum, Biotechnology, Computing, and Semiconductors. He emphasized India's commitment to becoming a global tech hub and protecting intellectual property, encouraging collaboration and innovation.